10-Q quarterly report · filed Nov 4, 2026

Sight Sciences, Inc. (SGHT) Q3 2026 10-Q Quarterly Report

Short answer

Sight Sciences, Inc. (SGHT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $25M (up 25.2% year over year) with net income of −$7M.

Q3 2026 key financials · XBRL

Revenue
$25M
+25.2% YoY · +6.6% QoQ
Net income
−$7M
+16.6% YoY · −53.2% QoQ
Operating margin
-24.6%
Gross margin
85.9%
EPS (diluted)
−$0.12
+20.0% YoY · −50.0% QoQ

Source: XBRL data from the Sight Sciences, Inc. (SGHT) Q3 2026 10-Q on SEC EDGAR. USD.

Sight Sciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $24.9M, up 25.2% YoY from $19.9M
  • Interventional Dry Eye strongest growth: $3.9M revenue vs $0.2M, gross margin 79.0% vs 37.8%
  • Interventional Glaucoma largest segment: $21.0M revenue, up 6.7% YoY
  • Total gross margin 85.9% vs 86.4% YoY, operating loss $6.1M vs $7.9M
  • Cash $77.4M; operating cash use $15.1M vs $27.9M, management expects liquidity beyond 12 months

Risk Factors

  • No material changes to risk factors since the Annual Report
  • Business, results, liquidity, and prospects vulnerable to identified or currently unknown risks
  • Common-stock trading price could decline, potentially causing total or partial investment loss

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Sight Sciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.